• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Focusing on the gut-kidney axis: the global clinical landscape of gut microbial therapy for kidney disease.

作者信息

Shi LuYao, Li Changyan, Fan WenXing

机构信息

Department of Nephrology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China.

Yunnan Key Laboratory of Organ Transplantation, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China.

出版信息

Int J Surg. 2025 Sep 1;111(9):6456-6459. doi: 10.1097/JS9.0000000000002679. Epub 2025 Jun 5.

DOI:10.1097/JS9.0000000000002679
PMID:40474802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12430877/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e483/12430877/7bdfccb8de9d/js9-111-6456-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e483/12430877/7bdfccb8de9d/js9-111-6456-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e483/12430877/7bdfccb8de9d/js9-111-6456-g001.jpg

相似文献

1
Focusing on the gut-kidney axis: the global clinical landscape of gut microbial therapy for kidney disease.聚焦肠道-肾脏轴：肠道微生物疗法治疗肾脏疾病的全球临床概况
Int J Surg. 2025 Sep 1;111(9):6456-6459. doi: 10.1097/JS9.0000000000002679. Epub 2025 Jun 5.
2
The influence of gut microbiota on the gut-brain-kidney axis and its implications for chronic kidney disease.肠道微生物群对肠-脑-肾轴的影响及其对慢性肾脏病的意义。
Front Microbiol. 2025 Jul 9;16:1535356. doi: 10.3389/fmicb.2025.1535356. eCollection 2025.
3
The gut-kidney axis in high-altitude hypoxia: pathophysiological mechanisms and the central role of hypoxia inducible factor.高原缺氧状态下的肠-肾轴：病理生理机制及缺氧诱导因子的核心作用
Ann Med. 2025 Dec;57(1):2557514. doi: 10.1080/07853890.2025.2557514. Epub 2025 Sep 12.
4
Kidney-Gut Axis in Chronic Kidney Disease: Therapeutic Perspectives from Microbiota Modulation and Nutrition.慢性肾脏病中的肾-肠轴：微生物群调节与营养的治疗前景
Nutrients. 2025 Jun 9;17(12):1961. doi: 10.3390/nu17121961.
5
Type 2 Diabetes and the Multifaceted Gut-X Axes.2型糖尿病与多维度的肠道-X轴
Nutrients. 2025 Aug 21;17(16):2708. doi: 10.3390/nu17162708.
6
Dual associations of gut and oral microbial networks with kidney transplantation.肠道和口腔微生物网络与肾移植的双重关联
mSystems. 2025 Aug 19;10(8):e0025225. doi: 10.1128/msystems.00252-25. Epub 2025 Jul 9.
7
Genomic Alterations and Microbiota Crosstalk in Hepatic Cancers: The Gut-Liver Axis in Tumorigenesis and Therapy.肝癌中的基因组改变与微生物群串扰：肿瘤发生与治疗中的肠-肝轴
Genes (Basel). 2025 Jul 30;16(8):920. doi: 10.3390/genes16080920.
8
Recent status and trends of innate immunity and the gut-kidney aixs in IgAN: A systematic review and bibliometric analysis.IgA 肾病中固有免疫和肠-肾轴的最新研究现状和趋势：系统评价和文献计量分析。
Int Immunopharmacol. 2024 Dec 25;143(Pt 2):113335. doi: 10.1016/j.intimp.2024.113335. Epub 2024 Oct 17.
9
Integrated oral-gut microbiota therapy: a novel perspective on preventing bacterial translocation for systemic disease management.口腔-肠道微生物群综合疗法：预防细菌易位以管理全身性疾病的新视角。
Front Cell Infect Microbiol. 2025 Jul 28;15:1641816. doi: 10.3389/fcimb.2025.1641816. eCollection 2025.
10
Microbial biotherapeutic metabolite alleviates liver injury by restoring hepatic lipid metabolism through PPARα across the gut-liver axis.微生物生物治疗代谢产物通过过氧化物酶体增殖物激活受体α（PPARα）恢复肠道-肝脏轴的肝脏脂质代谢，从而减轻肝损伤。
mBio. 2025 Sep 10;16(9):e0171825. doi: 10.1128/mbio.01718-25. Epub 2025 Aug 12.

本文引用的文献

1
Machine-learning assisted discovery unveils novel interplay between gut microbiota and host metabolic disturbance in diabetic kidney disease.机器学习辅助发现揭示了糖尿病肾病中肠道微生物群与宿主代谢紊乱之间的新型相互作用。
Gut Microbes. 2025 Dec;17(1):2473506. doi: 10.1080/19490976.2025.2473506. Epub 2025 Mar 6.
2
Risk-directed management of chronic kidney disease.慢性肾脏病的风险导向管理
Nat Rev Nephrol. 2025 May;21(5):287-298. doi: 10.1038/s41581-025-00931-8. Epub 2025 Jan 30.
3
Targeted gut microbiome therapy: Applications and prospects of probiotics, fecal microbiota transplantation and natural products in the management of type 2 diabetes.
靶向肠道微生物群疗法：益生菌、粪便微生物群移植和天然产物在2型糖尿病管理中的应用与前景
Pharmacol Res. 2025 Mar;213:107625. doi: 10.1016/j.phrs.2025.107625. Epub 2025 Jan 26.
4
The Efficacy and Safety of Probiotic Combinations Lobun Forte® Versus Renadyl® in Patients With Chronic Kidney Disease: A Comparative, Phase IV, Randomized, Open-Label, Active-Controlled, Parallel Study.益生菌组合Lobun Forte®与Renadyl®对慢性肾脏病患者的疗效和安全性：一项比较性、IV期、随机、开放标签、活性对照、平行研究。
Cureus. 2024 Aug 28;16(8):e67987. doi: 10.7759/cureus.67987. eCollection 2024 Aug.
5
The pathogenesis of IgA nephropathy and implications for treatment.IgA肾病的发病机制及其治疗意义。
Nat Rev Nephrol. 2025 Jan;21(1):9-23. doi: 10.1038/s41581-024-00885-3. Epub 2024 Sep 4.
6
Targeting Lactobacillus johnsonii to reverse chronic kidney disease.靶向约翰逊乳杆菌以逆转慢性肾脏病。
Signal Transduct Target Ther. 2024 Aug 5;9(1):195. doi: 10.1038/s41392-024-01913-1.
7
Changes in the Progression of Chronic Kidney Disease in Patients Undergoing Fecal Microbiota Transplantation.接受粪便微生物群移植的慢性肾脏病患者疾病进展的变化
Nutrients. 2024 Apr 10;16(8):1109. doi: 10.3390/nu16081109.